In this issue:
High rate of SpA concomitant with anterior uveitis
Guselkumab durably ameliorates a range of PsA manifestations
BE ACTIVE: sustained benefit of bimekizumab on symptoms
KEEPsAKE finds improved health-related QoL with risankizumab
Risk of infection during secukinumab vs TNF inhibitor treatment
US military study finds comparable incidence of AS between genders
Clinical and economic benefit of achieving disease control in PsA and AS
SELECT-PsA: durable efficacy for oral upadacitinib
Tapering and discontinuation of etanercept in patients with long-term MDA
Immunogenicity of CoronaVac vaccine in SpA
Please login below to download this issue (PDF)